Mark Bandyk

A PhAse 1b/2, Dose expansion, open-label study to eValuate sAfety and anti-tumor activity, of iNtravesiCal instillation of TARA-002 in adults with high-gradE non-muscle invasive blaDder cancer

Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Prostate Cancer Patients from Diverse Urology Practice Settings following Prolaris Testing

A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an anti-PD-1 antibody, in Combination with Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) Versus BCG (Induction and Maintenance) in Participants with High-Risk, BCG Naïve Non-Muscle Invasive Bladder Cancer

A Phase 2 Study of BC-819 in Patients with Non-Muscle Invasive Bladder Cancer Whose Disease is Unresponsive to Bacillus Calmette-Guerin